FDA’s accelerated approval guidance gets pushback from industry
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesClinical TrialsExpedited pathwaysGuidancePharmaceuticalsProduct LifecycleUnited StatesRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesClinical TrialsExpedited pathwaysGuidancePharmaceuticalsProduct LifecycleUnited States